The Long Pentraxin PTX3: A Biomarker Spanning From Cardiovascular Disorders to Cancer

Marco Falasca1,*, Fabrizia Bonacina2, Alberico Luigi Catapano2,3 and Giuseppe Danilo Norata1,2,4*

1Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, UK
2Department of Pharmacological and Bimolecular Sciences, Università degli Studi di Milano, Italy
3IRCCS Multimedica, Italy
4Center for the Study of Atherosclerosis, Società Italiana Studio Aterosclerosi, Ospedale Bassini, Italy

Abstract

Inflammatory mediators may play key roles in both atherosclerosis and cardiovascular disorders and in cancer. Pentraxins are a family of proteins characterized by the structural motif pentraxin domain. Long pentraxin 3 (PTX3), a protein that in humans is encoded by the PTX3 gene, is rapidly produced and released by several cell types in response to inflammatory stimuli. This review discusses the evidence supporting the role of PTX3 in predicting primary cardiovascular events and diagnosis and prognosis of cancer.

Keywords: PTX3; C-Reactive protein

Introduction

Pentraxins are essential components of the humoral arm of innate immunity and represent a family of soluble, multifunctional, pattern recognition proteins. Pentraxins are characterized by containing a conserved structural motif, the C-terminal pentraxin domain which in the case of Pentraxin 3 (PTX3) is coupled to an unrelated long N-terminal domain. Pentraxins are involved in acute immune-inflammatory responses and are divided into short, such as the C - reactive protein (CRP), and long pentraxins, such as PTX3 [1].

The pentraxin domain is highly conserved in mammals, in lower vertebrates and in arthropods. The PTX3 gene is highly conserved evolutionary making it possible to address the pathophysiological roles of human PTX3 using genetically modified mice [1]. This is not true for CRP. Furthermore, PTX3 plasma levels increase rapidly in both human and mice peaking at 6-8 hours [2-4] whereas CRP levels increase only in humans in 48 hours during the acute-phase response [1].

Evidence is accumulating indicating that increased PTX3 levels are also associated to cardiovascular disorders [5] and cancer [6,7]. In the last decade, PTX3 has been detected locally at sites of inflammation, such as in the myocardium and in the vasculature under different pathological conditions and in the tumour microenvironment. In addition, increased PTX3 plasma levels have been observed in patients as a consequence of rapid synthesis by various cell types. Data from animal models suggest that this increase might reflect a feedback mechanism involved in dampening an excessive inflammation rather than only the consequence of the activation of the immune-inflammatory system. On the basis of recent data, we will describe in the present review the possible use of PTX3 as a biomarker to improve diagnosis and prognosis of cardiovascular disorders and cancer.

PTX3 Involvement in Biological Pathways

PTX3 is the prototypic long pentraxin and is rapidly produced by different cell types, such as macrophages, neutrophils, Endothelial Cells (ECs), fibroblasts, vascular Smooth Muscle Cells (SMCs) and epithelial cells in response to several inflammatory cytokines, such as tumour necrosis a and interleukin-1β, TLR agonists and microbial components, including lipopolysaccharide (LPS) [8-10]. More recently also anti-inflammatory molecule were shown to modulate PTX3 expression such as IL-10 [11], Glucocorticoid Hormones (GCs) [12], and High-Density Lipoproteins (HDLs), which possess vascular protective properties [13]. HDLs induce PTX3 expression in endothelial cells [14] by the activating the phosphoinositide 3-kinase (PI3K)/Akt pathway through G-coupled lysoosphingolipid receptors. This is mimicked by sphingosine 1 phosphate (SIP) and others SIP mimetic [14] that are physiologically present in HDL and are responsible for some of the activities linking HDL to the immune inflammatory response [15].

PTX3 possesses multifunctional properties: similarly to short pentraxins, PTX3 recognizes the highly conserved Pathogen-Associated Molecular Patterns (PAMPs) expressed by microorganisms [16] and interacts with C1q, focolin-2 and Mannose-Binding Lectin (MBL) and therefore it modulates the activity of all the three-complement pathways [17], thus playing a crucial role in innate immune responses. More recently, additional unique roles have been discovered connecting PTX3 to inflammation and tissue remodelling. PTX3 competes with leukocyte PSGL-1, thus dampening the recruitment and extravasation of leukocytes mediated by P-selectin and limiting P-selectin-dependent inflammation [18]. Moreover, PTX3 binds with high affinity and selectivity Fibroblast Growth Factor (FGF)-2 [19,20], which in turn results in the inhibition of the interaction of FGF2 with tyrosine-kinase receptors (FGFRs) and Heparin Sulphate Proteoglycans (HSPGs) on the surface of endothelial; ECs and SMCs [21]. The FGF/FGFR system plays a crucial role not only in FGF2-dependent ECs proliferation [22] but also in SMCs proliferation, migration and survival in vitro [23-26]. These findings suggest that PTX3 is critically involved in both angiogenesis and restenosis, two typical phenomena associated to cancer and cardiovascular diseases.

*Corresponding authors: Marco Falasca, Blizard Institute, Queen Mary University of London, 4 Newark Street, E1 2AT London, UK; Tel: +44 20 78828243; Fax: +44 20 78822186; E-mail: m.falasca@qmul.ac.uk
Giuseppe Danilo Norata, Department of Pharmacological and Bimolecular Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy, Tel: +39 02 50318313; Fax: +39 02 50318386; E-mail: danilo.norata@unimi.it

Received July 26, 2013; Accepted August 18, 2013; Published August 19, 2013


Copyright: © 2013 Falasca M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
PTX3 as a Cardiovascular Biomarker

While PTX3 deficiency is associated with increased inflammation, cardiac damage [4] and atherosclerosis [27], PTX3 overexpression reduces carotid restenosis after angioplasty [19,20], thus suggesting a protective effect of PTX3 potentially associated with the tuning of inflammation in the context of cardiovascular disorders. Despite this, the role of PTX3 in human still remains controversial: increased plasma levels under diseased conditions might indicate that PTX3 is either a bystander of the inflammatory response or a further attempt to protection of our body. Indeed PTX3 plasma levels peak within 7.5 hours after Myocardial Infarction (MI), as compared to CRP which peaks around 50 hours [3]. In MI patients, PTX3 but not CRP independently predicted 3 months mortality after adjustment for major risk factors and other acute phase proteins [28]. Two large independent clinical trials (CORONA and GISSI-HF), showed that PTX3 was consistently associated with the outcomes in patients with heart failure and with a higher risk of all-cause cardiovascular mortality [29].

PTX3 as a Cancer Biomarker

Increased levels of PTX3 have been associated with cancer. PTX3 was identified by proteomic approaches as an important candidate biomarker for prostate cancer [6], lung cancer [7], liposarcomas [30] and more recently pancreatic carcinoma [31].

The role of PTX3 in cancer progression remains unknown. Molecular studies indicated that PTX3 exerts an anti-tumoral activity in prostate cancer by inhibiting FGFR2(FGFr8-dependent angiogenesis [32,33], potentiatorcine and paracrine activities on cancer cells that may contribute to tumour progression [34]. The GFG-binding domain was identified in the PTX3 N-terminus by monoclonal antibodies and surface plasmon resonance analysis [20], while TSG6, the secreted product of tumour necrosis factor-stimulated gene, was shown to revert the inhibitory effects exerted by PTX3 on GFG2-dependent angiogenesis through the interaction with the N-terminal domain of PTX3 [35]. Indeed, overexpression of the PTX3 N-terminus strongly inhibits the tumorigenic activity of TRAMP (Transgenic Adenocarcinoma Mouse Prostate)-C2 transfectants, whereas overexpression of the C-terminus has only a minor effect on tumour growth [32]. Although, PTX3 expression appears to be significantly down-regulated in various human prostate cancer datasets [36], a recent paper by Kondo et al. [31] found a strong correlation between pentraxin family member expression and prognosis of pancreatic carcinoma. The authors propose that pentraxin family members, especially PTX3, may be used as promising biomarkers in the prognosis of pancreatic carcinoma patients.

Given the strong correlation between impaired immune system activity and cancer, the possibility that increased PTX3 plasma levels are correlated to the immune-inflammatory response during cancer, similar to what reported in cardiovascular disorders [37], cannot be excluded.

Interestingly, in contrast with data obtained in prostate cancer, recent data suggest that PTX3 promotes tumour progression by preventing the phagocytosis of tumour cells induced by tumour-associated macrophages in nasopharyngeal carcinoma [38]. This suggests that PTX3 may be a key pro-tumorigenic player in the tumour microenvironment.

Several studies suggest that PTX3 is a potential cancer biomarker. By using proteomic approach five candidate biomarkers were found elevated in serum of lung cancer patients [39]. PTX3 is among these candidates and it was also identified as a candidate prostate [6] and breast [40] cancer biomarker by using a similar approach. Subsequent work has validated PTX3, but not other candidates, in a large cohort of lung carcinoma patients and controls [3]. Indeed, PTX3 serum elevation occurred in 50% of patients and correlated with the stage disease. PTX3 elevations in serum of lung cancer patients are associated with inflammation and cancer cell apoptosis around the tumour microenvironment.

Recently, PTX3 has been found to be secreted by several pancreatic carcinoma cell lines [13]. In addition, secreted PTX3 has been shown to promote cell migration in a concentration-dependent manner. Evaluation of clinical blood samples for pancreatic carcinoma patients revealed a strong correlation between blood PTX3 level and prognosis of the disease. Furthermore, the examination of the relationship between PTX3 and other pro-inflammatory mediators expression indicated that PTX3 is positively correlated with levels of CRP, interleukin-6 and macrophage-inhibitory factor. In a more recent study, the expression of PTX3 in gliomas was assessed by immunohistochemistry [41]. PTX3 expression differed across low and high-grade tumours based on histopathological diagnosis and clinical severity, positively correlating with tumour grade and severity.

Conclusions

PTX3 is an emerging biomarker with application in several pathological conditions including cardiovascular disorders and cancer. Nevertheless, more evidence is required in order to validate PTX3 as a biomarker with clinical utility either alone or as a member of a biomarker panel. Although the accumulating data pave the road for investigating the relevance of PTX3 as prognostic marker in different cancer conditions and in larger cohorts, several open questions remain: Are PTX3 plasma levels affected by cancer treatment? Are these changes related to the prognosis? Does PTX3 play a protective role in cancer similar to what reported in vitro and in animal studies for cardiovascular diseases? To what extent the ability of PTX3 to dampen FGF response contribute to limit cancer progression?

Answers to these questions and future studies on PTX3 expression in tissues and cells critically involved in both cardiovascular diseases and cancer, such as macrophages, will contribute to improve our understandings on the role of PTX3.

Acknowledgements

MF is supported by Pancreatic Cancer Research Fund and Prostate Cancer UK.ALC is supported by PUR 2009 University of Milan and by Fondazione Cariplo (2009-2582). GDN is supported by Fondazione Cariplo (2010-0768).

References


Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:

• 250 Open Access Journals
• 20,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing on PubMed (partial), Scopus, BIOSIS, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma